Breaking News

Rentschler Biotechnologie Names CEO

January 8, 2016

Mathias has more than 25 years of pharma and biopharma experience

Dr. Frank Mathias has been appointed chief executive officer of Rentschler Biotechnologie, effective 1 April 2016. Dr. Mathias was previously a member of the company’s supervisory board.
Former chief executive, Dr. Nikolaus F. Rentschler, is moving to the supervisory board to oversee further expansion of the Rentschler group.
Dr. Mathias has more than 25 years of experience in the pharma and biopharma industries. He served as chief executive officer of Servier Deutschland and Amgen Deutschland and in 2009 became chief executive officer at Medigene AG.
Dr. Rentschler said, “We are glad to have been able to take on such an experienced and successful CEO for Rentschler Biotechnologie. He is an expert in this business and has been familiar with the company’s topics for years. The shareholder, Members of the Supervisory Board and Management Board are looking forward to the cooperation.”
Dr. Frank Mathias, “I am impressed by the dynamics and the strong commitment of the leaders and staff of this growing company. On this basis and owing to continuously positive developments on the market we will jointly lead Rentschler Biotechnologie to future success.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks